For patients with EwS (especially those with detectable tumor-derived DNA), we observed a striking reduction of cfDNA fragment coverage for EwS-specific DHSs, EWS-FLI1 binding sites, and EWS-FLI1-correlated enhancers. This evidence concerns the gene FLI1 and neoplasm.